Results 81 to 90 of about 169 (91)

What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? [PDF]

Ther Adv Musculoskelet Dis
Taylor PC, Feist E, Pope JE, Nash P, Sibilia J, Caporali R, Balsa A.   +6 more
europepmc   +1 more source

Role of Interleukin-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Focus on the JAK/STAT Pathway and Macrophage Polarization. [PDF]

J Inflamm Res
Yu Z, Liu J, Chen L, Xie J.
europepmc   +1 more source

The significance of monitoring respiratory sample cultures and polymerase chain reaction tests for detecting bacterial pathogens in severely and critically ill patients with COVID-19. [PDF]

Afr J Thorac Crit Care Med
Strelkova D, Kuleshov V, Burmistrova E, Sychev I, Savochkina Y, Danilov D, Yatsyshina S, Glushchenko E, Elkina M, Ananicheva N, Yasneva A, Topolyanskaya S, Rachina S.   +12 more
europepmc   +1 more source

Efficacy of hemoadsorption in the severe course of COVID-19. [PDF]

Front Med (Lausanne)
Yakovlev AY, Ilyin YV, Bershadsky FF, Selivanov DD, Pevnev AA, Trikole AI, Popov AY, Pisarev VM.   +7 more
europepmc   +1 more source

Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match. [PDF]

BMJ Glob Health
Cokljat M, Cruz CV, Carrara VI, Puttaraksa K, Capriglioni C, Insaurralde SM, Rousseau-Portalis M, Roldan A, Watson JA, Tarning J, White NJ, Guerin PJ.   +11 more
europepmc   +1 more source

The results of thrombectomy from the arteries of the lower extremities in patients infected with SARS-CoV-2 Omicron variant with different severity of respiratory failure. [PDF]

Vascular
Kazantsev AN, Zharova AS, Shmatov DV, Zakeryaev AB, Lider RY, Kazantseva EG, Bagdavadze GS, Korotkikh AV, Lutsenko VA, Sultanov RV, Lebedev OV, Sirotkin AA, Snopova EV, Palagin PD.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rheumatic diseases and coronavirus infection: levilimab use experience

Medical alphabet, 2021
Background. Rheumatic diseases (RD) of autoimmune origin are considered as an important risk factor for infectious processes due to characteristic native immune system disorder, as well as due to the adverse effect of immunosuppressants and glucocorticoids on the mechanisms of anti-infective protection.Aim.
E. V. Kalinina, I. V. Lekareva, M. S. Zvonorenko, A. L. Emelianova, I. V. Kostryukova, E. V. Scherbinina, A. R. Babaeva   +6 more
openaire   +1 more source

Experience with Levilimab in Ambulatory Practice (in the Provision of Primary Medical and Social Care)

A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin, 2023
Purpose: The aim of the study was to confirm the effectiveness of the drug at the pre–hospital stage to prevent the development of severe forms of infection requiring hospitalization. Materials and methods: To collect clinical and epidemiological data in the 2021-2022 season, an active prospective cohort study approach was used to assess the efficacy ...
A.A. Slusar, P.A. Muraveva, M.V. Balyasin   +2 more
openaire   +1 more source

Interleukin-6 receptor inhibitor levilimab in the treatment of COVID-19 in patients with chronic kidney disease

Nephrology, 2023
Kim I.G. Kim, Frolov M.A. Frolov, Terentyeva N.V. Terentyeva, Sysoeva I.L. Sysoeva, Dyakova E.N. Dyakova, Usatyuk S.S. Usatyuk, Tomilina N.A. Tomilina, Frolova N.F. Frolova   +7 more
openaire   +1 more source

Comparative investigation of the efficacy of Cortexin®, Pineamine®, levilimab, adalimumab, and dexamethasone on cytokine storm models

Farmaciya (Pharmacy), 2021
A.V. Kalatanova, E.I. Trofimets, A.N. Afanasieva, V.B. Saparova, K.L. Kryshen, I.E. Makarenko   +5 more
openaire   +1 more source